News & Updates

The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.

Switching to the once-a-day, fixed-dose pill that contains bictegravir, emtricitabine, and tenofovir (BIC/FTC/TAF) appears to be safe and effective in older HIV patients and in people living with HIV (PLHIV) with pretreatment or treatment-acquired resistance, in addition to yielding metabolic benefits, according to studies presented at HIV Glasgow 2022.

The benefits of alcohol for cardiovascular disease (CVD) outcomes may have been overestimated by observational studies, according to a recent analysis.

Between 2015 and 2020, nearly a third of people living with HIV (PLHIV) in Asia-Pacific countries still show a detectable viral load, according to a study presented at the HIV Glasgow 2022 Congress.

Patients with idiopathic pulmonary fibrosis (IPF) who have extrapulmonary manifestations of a telomere syndrome show a decreased survival, according to a recent study.

Perceived public stigma (PPS) towards psychosis has remained static over 9 years in Hong Kong, with different education groups showing unique patterns of changes in PPS and endorsement of medication treatment across the years, researchers from the University of Hong Kong (HKU) have reported.